Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FGF1CP43
- Development stage
- Preclinical
- Lead developer
- Celon Pharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
FGF1CP43 (also known as M43) is a thermally stable recombinant human fibroblast growth factor 1 (FGF1) analogue developed by Celon Pharma in collaboration with the University of Wroclaw. It contains five specific mutations (Q55P, S62I, H108G, S114A, and L150D) designed to separate the glucose-lowering metabolic effects of FGF1 from its proliferative (mitogenic) properties. FGF1CP43 exhibits a high denaturation temperature of approximately 63°C, decreased binding affinity to the FGFR1IIIc receptor domain, and increased binding affinity to the insulin receptor (InsR). It is currently in preclinical development for the treatment of type 2 diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD).
- Other names
- FGF1 analogue M43FGF-1 analogue M43FGF 1 analogue M43FGF1-M43FGF-1-M43FGF 1-M43FGF1(Q55P/S62I/H108G/S114A/L150D)
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)INSR (Insulin receptor)
Beyond the preview
Go deeper on FGF1CP43.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FGF1CP43.